UK markets close in 11 minutes

Vivesto AB (0N4A.L)

LSE - LSE Delayed price. Currency in SEK
Add to watchlist
1.3180-0.3530 (-21.13%)
As of 03:06PM BST. Market open.

Vivesto AB

Gustav III:s Boulevard 46
5th floor
Solna 169 73
Sweden
46 18 50 54 40
https://www.vivesto.com

Sector(s)
Industry
Full-time employees22

Key executives

NameTitlePayExercisedYear born
Dr. Francois R. Martelet M.D.Chief Exec. Officer5.27MN/A1960
Mr. Fredrik JarrstenChief Financial OfficerN/AN/A1967
Mr. Kai WilkinsonChief Technical OfficerN/AN/A1981
Dr. Reinhard KoenigChief Scientific OfficerN/AN/A1960
Mr. Urban EkelundIR Mang.N/AN/AN/A
Ms. Och Annette LjungmarkHead of Accounting and HRN/AN/A1950
Mr. John T. CosbyHead of Regulatory AffairsN/AN/A1962
Mr. Dzianis BabrouHead of Product Devel.N/AN/AN/A
Mr. Henrik RönnbergChief Medical Officer of Animal HealthN/AN/AN/A
Maria Nilsson HagbergHead of Regulatory AffairsN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.

Description

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology primarily in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.

Corporate governance

Vivesto AB’s ISS governance QualityScore as of 1 May 2022 is 7. The pillar scores are Audit: 10; Board: 1; Shareholder rights: 1; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.